🔗 Share this article Novel Antibiotics Hailed as a 'Turning Point' in Combating Drug-Resistant Gonorrhea The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to scientists. A Worldwide Challenge Cases of gonorrhoea are increasing globally, with data suggesting more than 82 million new cases per year. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to those in 2014. “The approval of new treatments for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.” Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The WHO has designated it as a "critical concern". Ongoing monitoring showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024. A Pair of Novel Drugs Gain Authorization Zoliflodacin, also known as a brand name, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers hope that specific application of this new drug will help hinder the spread of drug resistance. Gepotidacin, developed by the drugmaker GSK, also received approval in concurrent days. This medication, which is also used to treat UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria. A Unique Approach to Creation Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it. “This approval signifies a significant shift in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.” Research Study Outcomes and Global Access According to data detailed in a major medical journal, the new drug cured the vast majority of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which involves two antibiotics. The research included nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US. As part of the agreement of its collaboration, GARDP has the ability to make available and distribute the drug in numerous regions with limited resources. Doctors directly involved have voiced positive views. Access to a single-dose, oral treatment of this kind is seen as a "revolutionary step" for managing the epidemic. This is considered essential to reduce the burden of the illness for people and to prevent the spread of extremely resistant gonorrhoea worldwide.